The initial dose was 10 mg of both fluoxetine and citalopram, and it was increased to 20 mg at 1 month and to 30 mg at the 6-month visit. 2012 Aug;19(8):848-55. doi: 10.1097/gme.0b013e3182476099.Walitt B, Urrútia G, Nishishinya MB, Cantrell SE, Häuser W.Cochrane Database Syst Rev.

Go back to normal dosage of citalopram.

Efficacy of citalopram as a monotherapy or as an adjunctive treatment to estrogen therapy for perimenopausal and postmenopausal women with depression and vasomotor symptoms. 12(1):18-26, 2005. Menopause and mood.

In this study, 38 women between the ages of 40 and 60 (15 peri-menopausal and 23 post-menopausal) with depressive disorders were randomized to receive open treatment with either escitalopram (flexible dosing of 10-20mg) or hormone therapy (norethindrone acetate and ethinyl estradiol). 2015 Jun 5;2015(6):CD011735. 2019 Oct 21;4(1):pkz088. Further research will examine the characteristics of symptomatic menopausal women who could better benefit from hormonal or non-hormonal interventions.These data were presented as a poster at the 2004 Annual Meeting of the American Psychiatric Association. They dont want to treat with me estrogen because of my past history of cancer. Clipboard, Search History, and several other advanced features are temporarily unavailable. that it took a good two weeks on a very slow build up to I think 10mg or may have been 20mg but anyway, a good bit of time to feel OK - almost like feeling worse before feeling better. While hormone therapy effectively treats insomnia and hot flashes, the results have been mixed in treating mood and anxiety symptoms. Prescribed under the brand name Celexa, citalopram is used to treat depression and sometimes prescribed for alcoholism, panic disorder, premenstrual dysphoric disorder, social phobia, or eating disorders. doi: 10.1002/14651858.CD009023.pub2.Wu CK, Tseng PT, Wu MK, Li DJ, Chen TY, Kuo FC, Stubbs B, Carvalho AF, Chen YW, Lin PY, Cheng YS, Sun CK.Sci Rep. 2020 May 15;10(1):8026. doi: 10.1038/s41598-020-64910-8.Leon-Ferre RA, Novotny PJ, Wolfe EG, Faubion SS, Ruddy KJ, Flora D, Dakhil CSR, Rowland KM, Graham ML, Le-Lindqwister N, Smith TJ, Loprinzi CL.JNCI Cancer Spectr. Please enable it to take advantage of the complete set of features! More recently, studies have identified an association between menopausal transition and an increased risk for developing depressive symptoms (Harlow et al., 2003; Freeman et al., 2004).

2007 Mar-Apr;24(2):448-61. doi: 10.1007/BF02849914.Ensrud KE, Joffe H, Guthrie KA, Larson JC, Reed SD, Newton KM, Sternfeld B, Lacroix AZ, Landis CA, Woods NF, Freeman EW.Menopause. eCollection 2020 Feb.Iliodromiti S, Wang W, Lumsden MA, Hunter MS, Bell R, Mishra G, Hickey M.BJOG. 2016 May;293(5):1007-13. doi: 10.1007/s00404-015-3900-1. lhfshbiologybiobio 265265anatomyphysiologyanatomy and physiologyanatphys. doi: 10.1002/14651858.CD011735.Cochrane Database Syst Rev. 1. 2019 Jan-Mar;10(1):6-13. doi: 10.4103/jmh.JMH_7_19.Breast Cancer Res Treat. The main outcome measures were hot flushes and Kupperman index. Epub 2019 Nov 13.J Midlife Health. After this 8-week extension phase, 60% (6/10) of the women achieved remission of depression with the addition of escitalopram.As significant improvements in depressive symptoms, quality of life and vasomotor symptoms were noted in both treatment groups, escitalopram may constitute an interesting treatment option for symptomatic menopausal women who are unable or unwilling to receive treatment with hormone therapy. Every year more than 1.7 million women in the United States enter into menopause. Soares CN, Joffe H, Steiner M. (2004).

Improvement in quality of life was also measured in both treatment groups.After 8 weeks, full remission of depression (defined as MADRS score < 10) was observed in 75%(12/16) of subjects treated with escitalopram versus 25% (4/16) treated with hormone therapy. Then increase to 20mg once a day. Menopause. The Montgomery-Asberg Depression Rating Scale (MADRS) was used to assess the severity of depressive symptoms.